Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HMR-3562. Aventis Pharma.

Z Ma1, A S Florjancic

  • 1Infectious Disease Research, Abbott Laboratories, Abbott Park, IL 60064-3537, USA. zhenkun.ma@abbott.com

Current Opinion in Investigational Drugs (London, England : 2000)
|March 15, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Supratentorial papillary glioneuronal tumors: a clinicopathological and genetic analysis of six cases].

Zhonghua bing li xue za zhi = Chinese journal of pathology·2026
Same author

Magneto-ionic control of magnetism through voltage-driven carbon transport.

Nature communications·2026
Same author

[Analysis of sensitization characteristics and changing trends of common allergens in a children's hospital in Shanghai City from 2020 to 2024].

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]·2025
Same author

Imaging pancreatic cancer with [<sup>18</sup>F]F-AlF-NOTA-FAPI-04 positron emission tomography/computed tomography (PET/CT): distribution patterns and therapeutic implications.

Clinical radiology·2025
Same author

[DICER1-mutant primary intracranial sarcoma: analysis of five cases].

Zhonghua bing li xue za zhi = Chinese journal of pathology·2025
Same author

Time dynamics of elevated glucose and beta-hydroxybutyrate on beta cell mitochondrial metabolism.

Islets·2025

Aventis Pharma is developing novel 2-fluoroketolides, HMR-3562 and HMR-3787, as potent antibacterial agents. These compounds show effectiveness against gram-positive bacteria and respiratory pathogens like Haemophilus influenzae.

Area of Science:

  • Pharmaceutical Science
  • Microbiology
  • Medicinal Chemistry

Background:

  • Antibiotic resistance necessitates the development of novel antibacterial agents.
  • Ketolides represent a promising class of antibiotics with a unique mechanism of action.
  • Gram-positive bacteria and respiratory pathogens pose significant public health challenges.

Purpose of the Study:

  • To investigate the antibacterial potential of novel 2-fluoroketolides, HMR-3562 and HMR-3787.
  • To evaluate the in vitro and in vivo efficacy of these compounds against key pathogens.

Main Methods:

  • Synthesis and characterization of 2-fluoroketolide compounds.
  • In vitro susceptibility testing against a panel of gram-positive bacteria and respiratory pathogens.
  • In vivo efficacy studies in relevant animal models.

Related Experiment Videos

Main Results:

  • HMR-3562 and HMR-3787 demonstrated significant in vitro potency against various gram-positive bacteria.
  • The compounds exhibited efficacy against respiratory tract pathogens, including Haemophilus influenzae.
  • In vivo studies confirmed the antibacterial activity of the investigated ketolides.

Conclusions:

  • Novel 2-fluoroketolides HMR-3562 and HMR-3787 show promise as potential antibacterial agents.
  • These compounds warrant further investigation for the treatment of bacterial infections, particularly those caused by gram-positive bacteria and Haemophilus influenzae.